The new EFPIA code on disclosure of transfers of value: a meaningful path to transparency?
This article was originally published in SRA
Executive Summary
Vincenzo Salvatore, Hae-Won Min Liao and Catherine Starks discuss the new code.
You may also be interested in...
Saudi FDA Wants Drug & Device Firms To Report Payments To Doctors, Health Institutions
The Saudi Food and Drug Authority has finalized the details of a new transparency initiative under which drug and medical device companies will have to disclose their financial relationships with healthcare professionals and institutions.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.